| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Guanine | 82 | 2011 | 208 | 7.980 |
Why?
|
| Antineoplastic Agents | 67 | 2023 | 2404 | 6.510 |
Why?
|
| Cisplatin | 37 | 2023 | 615 | 6.430 |
Why?
|
| Pharmacogenetics | 40 | 2022 | 441 | 6.160 |
Why?
|
| Polymorphism, Single Nucleotide | 68 | 2020 | 2399 | 5.700 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 80 | 2011 | 118 | 4.250 |
Why?
|
| Genome-Wide Association Study | 48 | 2022 | 1662 | 4.010 |
Why?
|
| Peripheral Nervous System Diseases | 10 | 2022 | 87 | 3.960 |
Why?
|
| Drug Resistance, Neoplasm | 30 | 2021 | 611 | 3.100 |
Why?
|
| Genetic Variation | 27 | 2019 | 1368 | 2.720 |
Why?
|
| Genome, Human | 25 | 2018 | 766 | 2.670 |
Why?
|
| Tinnitus | 5 | 2023 | 21 | 2.580 |
Why?
|
| Neoplasms | 26 | 2022 | 2998 | 2.560 |
Why?
|
| Testicular Neoplasms | 7 | 2023 | 113 | 2.460 |
Why?
|
| Methyltransferases | 50 | 2008 | 191 | 2.390 |
Why?
|
| Antineoplastic Agents, Alkylating | 24 | 2015 | 138 | 2.390 |
Why?
|
| Quantitative Trait Loci | 22 | 2017 | 606 | 2.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 8 | 2020 | 201 | 2.240 |
Why?
|
| Hearing Loss | 6 | 2023 | 59 | 2.230 |
Why?
|
| Antineoplastic Agents, Phytogenic | 12 | 2015 | 277 | 1.970 |
Why?
|
| Cancer Survivors | 6 | 2023 | 94 | 1.960 |
Why?
|
| Cell Line, Tumor | 36 | 2019 | 2531 | 1.940 |
Why?
|
| Cell Line | 40 | 2018 | 2498 | 1.790 |
Why?
|
| Carboplatin | 13 | 2018 | 303 | 1.750 |
Why?
|
| Paclitaxel | 10 | 2018 | 477 | 1.750 |
Why?
|
| Gene Expression | 16 | 2014 | 1310 | 1.720 |
Why?
|
| Carmustine | 34 | 2007 | 70 | 1.690 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2022 | 28 | 1.670 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 27 | 2021 | 2532 | 1.630 |
Why?
|
| Humans | 232 | 2023 | 88403 | 1.630 |
Why?
|
| Cyclophosphamide | 12 | 2014 | 300 | 1.620 |
Why?
|
| Gene Expression Regulation | 12 | 2021 | 1974 | 1.600 |
Why?
|
| Lymphocytes | 9 | 2018 | 469 | 1.580 |
Why?
|
| Apoptosis | 13 | 2014 | 1715 | 1.510 |
Why?
|
| Dacarbazine | 18 | 2014 | 102 | 1.500 |
Why?
|
| Antimetabolites, Antineoplastic | 9 | 2020 | 237 | 1.490 |
Why?
|
| Induced Pluripotent Stem Cells | 5 | 2021 | 112 | 1.380 |
Why?
|
| MicroRNAs | 7 | 2018 | 551 | 1.370 |
Why?
|
| Cell Proliferation | 9 | 2012 | 1640 | 1.290 |
Why?
|
| Drug Discovery | 4 | 2012 | 107 | 1.180 |
Why?
|
| Enzyme Inhibitors | 24 | 2009 | 645 | 1.170 |
Why?
|
| Etoposide | 8 | 2021 | 198 | 1.160 |
Why?
|
| Polymorphism, Genetic | 15 | 2015 | 824 | 1.140 |
Why?
|
| DNA Repair | 28 | 2007 | 359 | 1.110 |
Why?
|
| Precision Medicine | 5 | 2017 | 407 | 1.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 1256 | 1.090 |
Why?
|
| Neurons | 6 | 2021 | 1565 | 1.070 |
Why?
|
| Cytarabine | 7 | 2020 | 219 | 1.070 |
Why?
|
| Cell Survival | 21 | 2019 | 980 | 1.060 |
Why?
|
| Alkylating Agents | 7 | 2008 | 32 | 1.040 |
Why?
|
| Vincristine | 3 | 2021 | 112 | 1.030 |
Why?
|
| Genotype | 22 | 2020 | 1867 | 1.020 |
Why?
|
| Gene Expression Profiling | 13 | 2021 | 1424 | 0.950 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 199 | 0.940 |
Why?
|
| Camptothecin | 7 | 2009 | 191 | 0.940 |
Why?
|
| Glutathione Transferase | 5 | 2009 | 112 | 0.920 |
Why?
|
| Tumor Cells, Cultured | 33 | 2005 | 1056 | 0.880 |
Why?
|
| Biomarkers, Tumor | 6 | 2020 | 1519 | 0.870 |
Why?
|
| Brain Neoplasms | 13 | 2014 | 775 | 0.850 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2019 | 2322 | 0.840 |
Why?
|
| Speech Perception | 1 | 2022 | 71 | 0.820 |
Why?
|
| Cytosine | 6 | 2015 | 128 | 0.810 |
Why?
|
| Pemetrexed | 3 | 2018 | 76 | 0.810 |
Why?
|
| HapMap Project | 9 | 2014 | 47 | 0.800 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2021 | 393 | 0.800 |
Why?
|
| Genes | 2 | 2013 | 305 | 0.790 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2021 | 20 | 0.790 |
Why?
|
| Cytochrome P-450 Enzyme System | 5 | 2015 | 79 | 0.780 |
Why?
|
| Daunorubicin | 4 | 2014 | 78 | 0.750 |
Why?
|
| Organoplatinum Compounds | 3 | 2011 | 96 | 0.750 |
Why?
|
| Leukemia, Myeloid, Acute | 8 | 2020 | 782 | 0.740 |
Why?
|
| Phenotype | 16 | 2015 | 2431 | 0.730 |
Why?
|
| Cell Cycle Proteins | 3 | 2017 | 399 | 0.730 |
Why?
|
| Nuclear Proteins | 5 | 2015 | 727 | 0.710 |
Why?
|
| Colistin | 2 | 2017 | 7 | 0.700 |
Why?
|
| DNA, Neoplasm | 7 | 2006 | 269 | 0.690 |
Why?
|
| Population Groups | 2 | 2010 | 41 | 0.690 |
Why?
|
| Biomarkers, Pharmacological | 4 | 2012 | 21 | 0.690 |
Why?
|
| Genetic Linkage | 4 | 2008 | 624 | 0.690 |
Why?
|
| Membrane Proteins | 5 | 2018 | 1213 | 0.660 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2018 | 13 | 0.660 |
Why?
|
| Animals | 79 | 2021 | 27155 | 0.650 |
Why?
|
| Transcription Factors | 9 | 2017 | 1642 | 0.650 |
Why?
|
| Neoplasm Proteins | 4 | 2017 | 539 | 0.640 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 8 | 2011 | 697 | 0.640 |
Why?
|
| Drug Synergism | 16 | 2017 | 305 | 0.640 |
Why?
|
| Proteomics | 2 | 2017 | 227 | 0.630 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2015 | 310 | 0.630 |
Why?
|
| Liver | 15 | 2005 | 1241 | 0.620 |
Why?
|
| Ifosfamide | 4 | 2020 | 49 | 0.620 |
Why?
|
| Male | 68 | 2023 | 41917 | 0.620 |
Why?
|
| Transfection | 14 | 2007 | 912 | 0.600 |
Why?
|
| Electroporation | 3 | 2001 | 57 | 0.570 |
Why?
|
| CHO Cells | 10 | 2007 | 187 | 0.570 |
Why?
|
| Drug Therapy | 4 | 2011 | 70 | 0.560 |
Why?
|
| Antigens, CD34 | 3 | 2001 | 158 | 0.560 |
Why?
|
| Carboxylic Ester Hydrolases | 3 | 2002 | 24 | 0.550 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2006 | 299 | 0.550 |
Why?
|
| Fluorouracil | 7 | 2014 | 559 | 0.550 |
Why?
|
| Risk Factors | 9 | 2023 | 5434 | 0.550 |
Why?
|
| Carboxylesterase | 3 | 2004 | 10 | 0.520 |
Why?
|
| Proteins | 5 | 2014 | 786 | 0.520 |
Why?
|
| Cells, Cultured | 8 | 2021 | 2873 | 0.520 |
Why?
|
| Female | 64 | 2021 | 45647 | 0.510 |
Why?
|
| Carrier Proteins | 4 | 2015 | 679 | 0.510 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2018 | 1944 | 0.510 |
Why?
|
| Glioma | 6 | 2007 | 290 | 0.500 |
Why?
|
| Glutamates | 2 | 2011 | 89 | 0.500 |
Why?
|
| Alternative Splicing | 4 | 2012 | 210 | 0.490 |
Why?
|
| DNA Damage | 9 | 2011 | 371 | 0.480 |
Why?
|
| Antibiotics, Antineoplastic | 5 | 2014 | 116 | 0.480 |
Why?
|
| Mice | 38 | 2021 | 11690 | 0.480 |
Why?
|
| Gene Dosage | 3 | 2011 | 208 | 0.480 |
Why?
|
| Deoxycytidine | 2 | 2014 | 238 | 0.480 |
Why?
|
| Breast Neoplasms | 7 | 2020 | 2974 | 0.470 |
Why?
|
| Cricetinae | 13 | 2007 | 560 | 0.470 |
Why?
|
| Haplotypes | 4 | 2014 | 637 | 0.460 |
Why?
|
| Repressor Proteins | 1 | 2017 | 418 | 0.460 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1184 | 0.460 |
Why?
|
| Glutathione | 4 | 2004 | 109 | 0.450 |
Why?
|
| Adult | 31 | 2022 | 26278 | 0.440 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 63 | 0.440 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 39 | 0.440 |
Why?
|
| RNA-Binding Proteins | 2 | 2012 | 258 | 0.440 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 553 | 0.440 |
Why?
|
| Neuroblastoma | 2 | 2014 | 394 | 0.430 |
Why?
|
| DNA Methylation | 7 | 2015 | 655 | 0.430 |
Why?
|
| Universities | 1 | 2013 | 146 | 0.420 |
Why?
|
| Child | 14 | 2021 | 7078 | 0.420 |
Why?
|
| Glioblastoma | 9 | 2014 | 263 | 0.420 |
Why?
|
| Colonic Neoplasms | 10 | 1999 | 565 | 0.420 |
Why?
|
| Drug Resistance | 11 | 2018 | 232 | 0.420 |
Why?
|
| Inhibitory Concentration 50 | 6 | 2011 | 64 | 0.420 |
Why?
|
| Cortactin | 1 | 2011 | 11 | 0.410 |
Why?
|
| DNA Repair Enzymes | 3 | 2014 | 55 | 0.400 |
Why?
|
| Genomics | 5 | 2014 | 740 | 0.400 |
Why?
|
| Genealogy and Heraldry | 1 | 2011 | 13 | 0.400 |
Why?
|
| Inactivation, Metabolic | 1 | 2011 | 8 | 0.400 |
Why?
|
| Microsomes, Liver | 5 | 2015 | 49 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 774 | 0.390 |
Why?
|
| Lomustine | 9 | 1992 | 26 | 0.390 |
Why?
|
| Membrane Transport Proteins | 1 | 2012 | 169 | 0.380 |
Why?
|
| Aged | 27 | 2020 | 18887 | 0.380 |
Why?
|
| Gene Frequency | 6 | 2017 | 684 | 0.380 |
Why?
|
| Platinum Compounds | 3 | 2010 | 31 | 0.380 |
Why?
|
| Follow-Up Studies | 7 | 2020 | 3652 | 0.380 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2017 | 1348 | 0.380 |
Why?
|
| Chromosome Mapping | 5 | 2014 | 1077 | 0.370 |
Why?
|
| Pharmaceutical Preparations | 2 | 2011 | 91 | 0.370 |
Why?
|
| Epigenesis, Genetic | 3 | 2013 | 502 | 0.370 |
Why?
|
| RNA, Messenger | 7 | 2014 | 2005 | 0.370 |
Why?
|
| Middle Aged | 30 | 2020 | 25625 | 0.360 |
Why?
|
| Cell Cycle | 5 | 2004 | 508 | 0.360 |
Why?
|
| Transcriptome | 5 | 2015 | 619 | 0.360 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2009 | 15 | 0.360 |
Why?
|
| Databases, Genetic | 6 | 2012 | 263 | 0.350 |
Why?
|
| Linkage Disequilibrium | 6 | 2013 | 474 | 0.350 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2003 | 85 | 0.350 |
Why?
|
| Genes, Regulator | 1 | 2009 | 65 | 0.340 |
Why?
|
| Promoter Regions, Genetic | 7 | 2014 | 956 | 0.340 |
Why?
|
| Capecitabine | 4 | 2020 | 98 | 0.340 |
Why?
|
| Mice, Nude | 18 | 2005 | 814 | 0.340 |
Why?
|
| Biomedical Research | 1 | 2013 | 388 | 0.330 |
Why?
|
| Hyaluronan Receptors | 1 | 2009 | 38 | 0.330 |
Why?
|
| Folic Acid | 1 | 2009 | 62 | 0.330 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 742 | 0.330 |
Why?
|
| Inheritance Patterns | 1 | 2008 | 48 | 0.320 |
Why?
|
| DNA | 14 | 2011 | 1308 | 0.320 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2008 | 447 | 0.320 |
Why?
|
| DNA Copy Number Variations | 1 | 2009 | 176 | 0.320 |
Why?
|
| Cation Transport Proteins | 1 | 2008 | 67 | 0.310 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 736 | 0.310 |
Why?
|
| Sex Characteristics | 2 | 2009 | 320 | 0.310 |
Why?
|
| Young Adult | 9 | 2021 | 6188 | 0.310 |
Why?
|
| Gene Silencing | 2 | 2015 | 178 | 0.310 |
Why?
|
| Population | 1 | 2008 | 35 | 0.310 |
Why?
|
| Phosphoramide Mustards | 3 | 2004 | 4 | 0.310 |
Why?
|
| RNA, Small Interfering | 4 | 2015 | 558 | 0.310 |
Why?
|
| Chromosomes, Human | 1 | 2008 | 66 | 0.310 |
Why?
|
| Anticarcinogenic Agents | 2 | 2000 | 73 | 0.310 |
Why?
|
| Pyrazines | 2 | 2000 | 94 | 0.300 |
Why?
|
| Antigens, Differentiation | 2 | 2005 | 141 | 0.300 |
Why?
|
| Comprehension | 1 | 2008 | 80 | 0.300 |
Why?
|
| Exons | 5 | 2012 | 452 | 0.300 |
Why?
|
| Prognosis | 9 | 2020 | 3747 | 0.300 |
Why?
|
| Survivors | 3 | 2022 | 233 | 0.300 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2021 | 93 | 0.300 |
Why?
|
| Cell Division | 11 | 2003 | 696 | 0.290 |
Why?
|
| Signal Transduction | 5 | 2014 | 3361 | 0.290 |
Why?
|
| Lung Neoplasms | 4 | 2021 | 2332 | 0.290 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2014 | 289 | 0.290 |
Why?
|
| Geographic Information Systems | 1 | 2006 | 23 | 0.280 |
Why?
|
| Methylnitronitrosoguanidine | 7 | 1991 | 16 | 0.280 |
Why?
|
| Endoplasmic Reticulum | 1 | 2008 | 252 | 0.280 |
Why?
|
| Alkyl and Aryl Transferases | 4 | 1999 | 15 | 0.280 |
Why?
|
| Spermine | 2 | 1998 | 21 | 0.280 |
Why?
|
| Transplantation, Heterologous | 16 | 2007 | 371 | 0.280 |
Why?
|
| Genome | 2 | 2006 | 376 | 0.270 |
Why?
|
| Colorectal Neoplasms | 4 | 2014 | 966 | 0.270 |
Why?
|
| Computational Biology | 7 | 2014 | 536 | 0.270 |
Why?
|
| Biomarkers | 3 | 2021 | 1754 | 0.270 |
Why?
|
| Mutation | 9 | 2008 | 4092 | 0.270 |
Why?
|
| Mycosis Fungoides | 2 | 2011 | 29 | 0.270 |
Why?
|
| Neoplasm Transplantation | 14 | 2002 | 396 | 0.270 |
Why?
|
| Health Status | 1 | 2008 | 368 | 0.260 |
Why?
|
| Rats | 21 | 2015 | 4027 | 0.260 |
Why?
|
| Adolescent | 8 | 2021 | 9134 | 0.260 |
Why?
|
| Mitomycin | 1 | 2005 | 29 | 0.260 |
Why?
|
| Kinetics | 13 | 2003 | 1528 | 0.260 |
Why?
|
| Models, Biological | 5 | 2018 | 1764 | 0.260 |
Why?
|
| Head and Neck Neoplasms | 8 | 2011 | 1057 | 0.250 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2004 | 7 | 0.250 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 759 | 0.240 |
Why?
|
| Cytochrome P-450 CYP1A2 | 2 | 2001 | 4 | 0.240 |
Why?
|
| Cell Death | 4 | 2011 | 262 | 0.240 |
Why?
|
| Platinum | 3 | 2011 | 63 | 0.230 |
Why?
|
| Chromatography, High Pressure Liquid | 6 | 1999 | 315 | 0.230 |
Why?
|
| Tubulin | 2 | 2015 | 58 | 0.230 |
Why?
|
| RNA Interference | 3 | 2014 | 377 | 0.230 |
Why?
|
| Tissue Distribution | 6 | 2004 | 292 | 0.230 |
Why?
|
| Case-Control Studies | 6 | 2020 | 1848 | 0.230 |
Why?
|
| Biotransformation | 6 | 2009 | 50 | 0.220 |
Why?
|
| Survival Analysis | 3 | 2006 | 1542 | 0.220 |
Why?
|
| Mesylates | 5 | 1991 | 15 | 0.220 |
Why?
|
| Base Sequence | 10 | 2014 | 2331 | 0.220 |
Why?
|
| Proteome | 2 | 2014 | 130 | 0.220 |
Why?
|
| Chromosomes, Human, X | 2 | 2015 | 55 | 0.220 |
Why?
|
| Treatment Outcome | 11 | 2013 | 8139 | 0.220 |
Why?
|
| Prodrugs | 2 | 2004 | 49 | 0.210 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2015 | 183 | 0.210 |
Why?
|
| Leukemia | 4 | 2009 | 321 | 0.210 |
Why?
|
| Cytosol | 4 | 2011 | 190 | 0.210 |
Why?
|
| Astrocytoma | 2 | 2000 | 82 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 470 | 0.210 |
Why?
|
| Sensation Disorders | 1 | 2022 | 24 | 0.210 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2013 | 124 | 0.210 |
Why?
|
| Cohort Studies | 3 | 2021 | 2832 | 0.200 |
Why?
|
| Speech | 1 | 2022 | 85 | 0.200 |
Why?
|
| Blotting, Western | 6 | 2011 | 797 | 0.200 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2013 | 201 | 0.200 |
Why?
|
| Hypercholesterolemia | 1 | 2023 | 159 | 0.200 |
Why?
|
| Antibodies | 3 | 2014 | 354 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 891 | 0.200 |
Why?
|
| Methylnitrosourea | 4 | 1989 | 7 | 0.200 |
Why?
|
| Survival Rate | 4 | 2020 | 1881 | 0.200 |
Why?
|
| Kidney | 6 | 2013 | 1145 | 0.200 |
Why?
|
| Hydrolysis | 4 | 2004 | 142 | 0.200 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 76 | 0.190 |
Why?
|
| Drug Interactions | 5 | 2005 | 248 | 0.190 |
Why?
|
| CpG Islands | 4 | 2015 | 158 | 0.190 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2021 | 50 | 0.190 |
Why?
|
| Oligodeoxyribonucleotides | 4 | 1988 | 127 | 0.190 |
Why?
|
| Drug Administration Schedule | 7 | 2009 | 902 | 0.190 |
Why?
|
| Codon | 2 | 1999 | 122 | 0.190 |
Why?
|
| Vinblastine | 1 | 2020 | 108 | 0.180 |
Why?
|
| Fetal Blood | 1 | 2001 | 90 | 0.180 |
Why?
|
| Gene Transfer Techniques | 1 | 2001 | 152 | 0.180 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 245 | 0.180 |
Why?
|
| Bleomycin | 1 | 2020 | 102 | 0.180 |
Why?
|
| Deoxycytidine Kinase | 2 | 2011 | 4 | 0.180 |
Why?
|
| Oxidoreductases | 3 | 1999 | 112 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2002 | 154 | 0.180 |
Why?
|
| Cell Differentiation | 2 | 2017 | 1513 | 0.180 |
Why?
|
| Ketoconazole | 1 | 2000 | 26 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 11 | 2005 | 1084 | 0.180 |
Why?
|
| Genetic Testing | 2 | 2017 | 536 | 0.170 |
Why?
|
| Colonic Polyps | 1 | 2000 | 129 | 0.170 |
Why?
|
| Escherichia coli | 7 | 1993 | 604 | 0.170 |
Why?
|
| Myosin Type II | 1 | 2019 | 50 | 0.170 |
Why?
|
| Myosin Heavy Chains | 1 | 2019 | 92 | 0.170 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 246 | 0.170 |
Why?
|
| Isoenzymes | 4 | 2001 | 272 | 0.160 |
Why?
|
| Antigens, CD | 1 | 2001 | 464 | 0.160 |
Why?
|
| Hypogonadism | 1 | 2019 | 40 | 0.160 |
Why?
|
| Taxoids | 2 | 2016 | 130 | 0.160 |
Why?
|
| Radiotherapy | 2 | 2020 | 331 | 0.160 |
Why?
|
| Time Factors | 11 | 2014 | 5301 | 0.160 |
Why?
|
| Area Under Curve | 4 | 2008 | 333 | 0.160 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 108 | 0.160 |
Why?
|
| Vagina | 1 | 2020 | 170 | 0.160 |
Why?
|
| Structure-Activity Relationship | 8 | 2001 | 411 | 0.160 |
Why?
|
| Naphthoquinones | 1 | 1998 | 5 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 6 | 2016 | 3196 | 0.160 |
Why?
|
| Linear Models | 2 | 2011 | 423 | 0.160 |
Why?
|
| Pyrimidines | 3 | 1996 | 372 | 0.160 |
Why?
|
| Molecular Sequence Data | 9 | 2011 | 3028 | 0.150 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 6706 | 0.150 |
Why?
|
| Protein Isoforms | 3 | 2012 | 272 | 0.150 |
Why?
|
| Recombinant Proteins | 6 | 2007 | 1019 | 0.150 |
Why?
|
| Self Report | 1 | 2019 | 294 | 0.150 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2009 | 74 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 2 | 2 | 2009 | 25 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 2 | 2010 | 119 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 6 | 2014 | 78 | 0.140 |
Why?
|
| Medulloblastoma | 5 | 2005 | 36 | 0.140 |
Why?
|
| Bacteria | 2 | 2020 | 466 | 0.140 |
Why?
|
| Cell Line, Transformed | 2 | 2008 | 155 | 0.140 |
Why?
|
| Age of Onset | 1 | 2017 | 311 | 0.140 |
Why?
|
| Ethylnitrosourea | 2 | 1988 | 30 | 0.140 |
Why?
|
| DNA Modification Methylases | 2 | 2014 | 28 | 0.140 |
Why?
|
| Mutagenicity Tests | 3 | 2006 | 6 | 0.140 |
Why?
|
| Streptozocin | 7 | 1994 | 55 | 0.130 |
Why?
|
| Polyneuropathies | 1 | 2016 | 27 | 0.130 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 48 | 0.130 |
Why?
|
| Child, Preschool | 6 | 2015 | 3668 | 0.130 |
Why?
|
| Introns | 3 | 2012 | 298 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 282 | 0.130 |
Why?
|
| Quality of Life | 4 | 2020 | 1646 | 0.130 |
Why?
|
| Mice, Knockout | 3 | 2016 | 1986 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2015 | 7 | 0.130 |
Why?
|
| X Chromosome Inactivation | 1 | 2015 | 28 | 0.130 |
Why?
|
| Half-Life | 3 | 2003 | 96 | 0.130 |
Why?
|
| Thymine | 4 | 1988 | 17 | 0.130 |
Why?
|
| Flow Cytometry | 3 | 2003 | 691 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2000 | 1231 | 0.130 |
Why?
|
| Epistasis, Genetic | 2 | 2013 | 89 | 0.130 |
Why?
|
| Acrolein | 2 | 2007 | 5 | 0.130 |
Why?
|
| Acetaldehyde | 2 | 2007 | 7 | 0.130 |
Why?
|
| Neurites | 1 | 2015 | 36 | 0.130 |
Why?
|
| Databases, Nucleic Acid | 1 | 2015 | 41 | 0.130 |
Why?
|
| Pedigree | 2 | 2008 | 968 | 0.130 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2015 | 64 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2014 | 289 | 0.120 |
Why?
|
| Oxygenases | 1 | 2014 | 13 | 0.120 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2014 | 18 | 0.120 |
Why?
|
| Deoxyguanosine | 3 | 2004 | 28 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2012 | 863 | 0.120 |
Why?
|
| Body Weight | 4 | 2013 | 452 | 0.120 |
Why?
|
| Hand-Foot Syndrome | 1 | 2014 | 1 | 0.120 |
Why?
|
| Infusions, Intravenous | 3 | 2007 | 430 | 0.120 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 119 | 0.120 |
Why?
|
| Cyclohexylamines | 1 | 2014 | 7 | 0.120 |
Why?
|
| Cricetulus | 3 | 2007 | 126 | 0.120 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 1994 | 5 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 1999 | 577 | 0.120 |
Why?
|
| Eye Proteins | 1 | 2015 | 128 | 0.120 |
Why?
|
| Carcinoma | 2 | 1989 | 441 | 0.120 |
Why?
|
| HEK293 Cells | 2 | 2013 | 635 | 0.120 |
Why?
|
| Plicamycin | 1 | 2013 | 9 | 0.120 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 229 | 0.120 |
Why?
|
| DNA Mismatch Repair | 2 | 2011 | 55 | 0.120 |
Why?
|
| 5' Untranslated Regions | 2 | 2004 | 51 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 1998 | 1763 | 0.120 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2013 | 6 | 0.120 |
Why?
|
| Glycerol | 1 | 1994 | 33 | 0.120 |
Why?
|
| Quality Control | 1 | 2014 | 116 | 0.120 |
Why?
|
| Epithelial Cells | 1 | 2018 | 686 | 0.110 |
Why?
|
| Amino Acid Sequence | 5 | 2005 | 2061 | 0.110 |
Why?
|
| DNA-Binding Proteins | 4 | 2014 | 1238 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2012 | 217 | 0.110 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 64 | 0.110 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2012 | 12 | 0.110 |
Why?
|
| Interleukin-11 | 1 | 2013 | 20 | 0.110 |
Why?
|
| Injections, Intravenous | 4 | 2006 | 241 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 394 | 0.110 |
Why?
|
| Alleles | 3 | 2005 | 1131 | 0.110 |
Why?
|
| Methylation | 6 | 2011 | 265 | 0.110 |
Why?
|
| Caspase 1 | 1 | 2012 | 18 | 0.110 |
Why?
|
| 3' Untranslated Regions | 2 | 2004 | 95 | 0.110 |
Why?
|
| Salmonella Infections | 1 | 2012 | 18 | 0.110 |
Why?
|
| Age Factors | 1 | 2017 | 1857 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2014 | 2285 | 0.110 |
Why?
|
| Salmonella typhimurium | 1 | 2012 | 32 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2012 | 24 | 0.110 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 2 | 2008 | 36 | 0.110 |
Why?
|
| Multifactorial Inheritance | 1 | 2014 | 167 | 0.100 |
Why?
|
| In Vitro Techniques | 5 | 2015 | 995 | 0.100 |
Why?
|
| Methionine | 1 | 2012 | 65 | 0.100 |
Why?
|
| Mutagenesis | 2 | 2008 | 200 | 0.100 |
Why?
|
| Nigeria | 1 | 2012 | 155 | 0.100 |
Why?
|
| Students | 1 | 2013 | 162 | 0.100 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2002 | 269 | 0.100 |
Why?
|
| Floxuridine | 1 | 2011 | 11 | 0.100 |
Why?
|
| Southwestern United States | 1 | 2011 | 8 | 0.100 |
Why?
|
| 5'-Nucleotidase | 1 | 2011 | 13 | 0.100 |
Why?
|
| Sezary Syndrome | 1 | 2011 | 12 | 0.100 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2009 | 72 | 0.100 |
Why?
|
| Germ Cells | 1 | 2012 | 130 | 0.100 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2009 | 66 | 0.100 |
Why?
|
| Polyethylene Glycols | 1 | 1994 | 365 | 0.100 |
Why?
|
| Twins, Monozygotic | 1 | 2011 | 57 | 0.100 |
Why?
|
| Interleukin-3 | 2 | 2001 | 36 | 0.100 |
Why?
|
| Hypertension | 1 | 2017 | 730 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 212 | 0.100 |
Why?
|
| Drug Labeling | 1 | 2011 | 41 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 307 | 0.100 |
Why?
|
| Caspases | 1 | 2011 | 156 | 0.100 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 1212 | 0.100 |
Why?
|
| DNA, Complementary | 2 | 2002 | 392 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 3 | 2008 | 272 | 0.090 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2001 | 112 | 0.090 |
Why?
|
| HeLa Cells | 3 | 1988 | 505 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 133 | 0.090 |
Why?
|
| Loss of Heterozygosity | 3 | 2007 | 86 | 0.090 |
Why?
|
| Escherichia coli Proteins | 1 | 1991 | 182 | 0.090 |
Why?
|
| Cluster Analysis | 4 | 2013 | 371 | 0.090 |
Why?
|
| Mutagens | 2 | 2000 | 31 | 0.090 |
Why?
|
| Semustine | 1 | 1990 | 2 | 0.090 |
Why?
|
| Cell Culture Techniques | 2 | 2001 | 192 | 0.090 |
Why?
|
| Rhabdomyosarcoma | 2 | 2003 | 42 | 0.090 |
Why?
|
| Vinca Alkaloids | 1 | 2009 | 3 | 0.090 |
Why?
|
| Neutropenia | 2 | 2009 | 216 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2004 | 927 | 0.090 |
Why?
|
| Software | 2 | 2014 | 661 | 0.090 |
Why?
|
| Topoisomerase II Inhibitors | 3 | 2011 | 27 | 0.090 |
Why?
|
| Open Reading Frames | 1 | 2009 | 119 | 0.080 |
Why?
|
| Anthracyclines | 1 | 2009 | 38 | 0.080 |
Why?
|
| Amino Acid Transport Systems, Basic | 1 | 2008 | 1 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2001 | 565 | 0.080 |
Why?
|
| Semaphorins | 1 | 2008 | 17 | 0.080 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2008 | 12 | 0.080 |
Why?
|
| Copper-transporting ATPases | 1 | 2008 | 12 | 0.080 |
Why?
|
| RNA Precursors | 1 | 2009 | 71 | 0.080 |
Why?
|
| Genetic Markers | 1 | 2010 | 478 | 0.080 |
Why?
|
| Models, Genetic | 3 | 2014 | 942 | 0.080 |
Why?
|
| Multidrug Resistance-Associated Proteins | 3 | 2009 | 27 | 0.080 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2009 | 80 | 0.080 |
Why?
|
| Lod Score | 1 | 2008 | 152 | 0.080 |
Why?
|
| Glypicans | 1 | 2008 | 6 | 0.080 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 314 | 0.080 |
Why?
|
| Caspase 12 | 1 | 2008 | 1 | 0.080 |
Why?
|
| Transcription Factor CHOP | 1 | 2008 | 15 | 0.080 |
Why?
|
| Chicago | 1 | 2013 | 1408 | 0.080 |
Why?
|
| Thiones | 2 | 2000 | 10 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 77 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 1996 | 743 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2009 | 113 | 0.080 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2008 | 9 | 0.080 |
Why?
|
| Epoxide Hydrolases | 1 | 2008 | 7 | 0.080 |
Why?
|
| Neurofibromin 1 | 1 | 2008 | 8 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2011 | 489 | 0.080 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2009 | 109 | 0.080 |
Why?
|
| Melphalan | 2 | 2001 | 98 | 0.080 |
Why?
|
| Thiophenes | 2 | 2000 | 43 | 0.080 |
Why?
|
| Cross-Linking Reagents | 1 | 1988 | 86 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2008 | 161 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 44 | 0.080 |
Why?
|
| Nucleic Acid Conformation | 1 | 2009 | 338 | 0.080 |
Why?
|
| Drug Delivery Systems | 2 | 2007 | 179 | 0.080 |
Why?
|
| Peptides | 1 | 1991 | 646 | 0.080 |
Why?
|
| Adenosine Triphosphatases | 1 | 2008 | 154 | 0.080 |
Why?
|
| Biological Transport | 1 | 2008 | 399 | 0.080 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 2743 | 0.080 |
Why?
|
| Biological Availability | 2 | 2000 | 93 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2011 | 340 | 0.080 |
Why?
|
| Oxazines | 1 | 2007 | 13 | 0.080 |
Why?
|
| Obesity | 1 | 2014 | 968 | 0.080 |
Why?
|
| Xanthenes | 1 | 2007 | 23 | 0.070 |
Why?
|
| Transcription Factor RelA | 1 | 2007 | 49 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2008 | 146 | 0.070 |
Why?
|
| Gene Deletion | 1 | 2008 | 341 | 0.070 |
Why?
|
| Hematopoiesis | 1 | 2008 | 164 | 0.070 |
Why?
|
| Fibroblasts | 3 | 2008 | 754 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2006 | 1568 | 0.070 |
Why?
|
| Oncogenes | 1 | 2007 | 92 | 0.070 |
Why?
|
| DNA Adducts | 2 | 2009 | 21 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 594 | 0.070 |
Why?
|
| Nitrosourea Compounds | 2 | 2002 | 9 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2008 | 173 | 0.070 |
Why?
|
| Binding Sites | 2 | 2003 | 1112 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2000 | 684 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 2334 | 0.070 |
Why?
|
| Nitrosamines | 2 | 1988 | 8 | 0.070 |
Why?
|
| Alkylation | 5 | 2004 | 31 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1998 | 205 | 0.070 |
Why?
|
| Thymidine | 1 | 1985 | 59 | 0.070 |
Why?
|
| Oxidation-Reduction | 2 | 1998 | 379 | 0.070 |
Why?
|
| Activin Receptors, Type I | 1 | 2005 | 13 | 0.070 |
Why?
|
| United States | 3 | 2017 | 6871 | 0.070 |
Why?
|
| Substrate Specificity | 6 | 1995 | 351 | 0.070 |
Why?
|
| Physicians | 1 | 2013 | 684 | 0.070 |
Why?
|
| Protein Phosphatase 1 | 1 | 2005 | 34 | 0.070 |
Why?
|
| Base Pair Mismatch | 1 | 2005 | 27 | 0.070 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2005 | 45 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 511 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2003 | 404 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 1991 | 884 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2007 | 269 | 0.060 |
Why?
|
| Crosses, Genetic | 1 | 2005 | 171 | 0.060 |
Why?
|
| Cell Transformation, Viral | 1 | 2005 | 40 | 0.060 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 231 | 0.060 |
Why?
|
| Random Allocation | 1 | 2005 | 329 | 0.060 |
Why?
|
| Glutathione Peroxidase | 1 | 2004 | 24 | 0.060 |
Why?
|
| Dimethylnitrosamine | 1 | 1984 | 4 | 0.060 |
Why?
|
| Diethylnitrosamine | 1 | 1984 | 7 | 0.060 |
Why?
|
| Polydeoxyribonucleotides | 1 | 1984 | 5 | 0.060 |
Why?
|
| Aziridines | 1 | 2004 | 9 | 0.060 |
Why?
|
| Poly T | 1 | 1984 | 2 | 0.060 |
Why?
|
| Procaine | 1 | 2004 | 11 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2013 | 298 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 1142 | 0.060 |
Why?
|
| Organ Size | 1 | 2005 | 367 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 603 | 0.060 |
Why?
|
| Cattle | 3 | 1999 | 375 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2003 | 417 | 0.060 |
Why?
|
| Hydroxamic Acids | 1 | 2004 | 51 | 0.060 |
Why?
|
| Plasmids | 2 | 2003 | 292 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2019 | 685 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2009 | 1095 | 0.060 |
Why?
|
| Homozygote | 1 | 2004 | 202 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2004 | 203 | 0.060 |
Why?
|
| Germ-Line Mutation | 2 | 2020 | 341 | 0.060 |
Why?
|
| Sarcoma | 1 | 2006 | 220 | 0.060 |
Why?
|
| Genes, ras | 3 | 2009 | 97 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2003 | 217 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2007 | 464 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2005 | 212 | 0.060 |
Why?
|
| Annexin A5 | 1 | 2003 | 20 | 0.060 |
Why?
|
| Indoles | 1 | 2005 | 309 | 0.060 |
Why?
|
| Transcription Initiation Site | 1 | 2003 | 46 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2003 | 79 | 0.060 |
Why?
|
| DNA Primers | 3 | 2005 | 543 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 2007 | 427 | 0.050 |
Why?
|
| Subcellular Fractions | 2 | 2007 | 94 | 0.050 |
Why?
|
| Lung | 2 | 2005 | 1241 | 0.050 |
Why?
|
| Isoelectric Focusing | 1 | 2002 | 39 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 36 | 0.050 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 3 | 1999 | 29 | 0.050 |
Why?
|
| DNA Topoisomerases, Type II | 2 | 2009 | 21 | 0.050 |
Why?
|
| Gene Library | 1 | 2002 | 133 | 0.050 |
Why?
|
| Chlorambucil | 1 | 2001 | 23 | 0.050 |
Why?
|
| Infant | 4 | 2012 | 3110 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2005 | 496 | 0.050 |
Why?
|
| Thrombopoietin | 1 | 2001 | 12 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2014 | 767 | 0.050 |
Why?
|
| Stem Cell Factor | 1 | 2001 | 19 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2020 | 4265 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 647 | 0.050 |
Why?
|
| A549 Cells | 1 | 2021 | 41 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 1 | 2001 | 40 | 0.050 |
Why?
|
| Organ Specificity | 2 | 2001 | 270 | 0.050 |
Why?
|
| NAD+ Nucleosidase | 1 | 2001 | 2 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2001 | 6 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2001 | 12 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2017 | 478 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2002 | 235 | 0.050 |
Why?
|
| Plasma | 1 | 2001 | 51 | 0.050 |
Why?
|
| Nervous System Neoplasms | 1 | 2000 | 11 | 0.050 |
Why?
|
| Risk | 2 | 2012 | 660 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2001 | 216 | 0.050 |
Why?
|
| Biopsy | 2 | 2003 | 1187 | 0.050 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2001 | 144 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2001 | 275 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 27 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 166 | 0.050 |
Why?
|
| Phenanthridines | 1 | 2000 | 24 | 0.040 |
Why?
|
| Genetic Association Studies | 2 | 2013 | 294 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2001 | 307 | 0.040 |
Why?
|
| Molecular Structure | 2 | 1998 | 289 | 0.040 |
Why?
|
| Hot Temperature | 1 | 2000 | 206 | 0.040 |
Why?
|
| Transferases | 2 | 1997 | 23 | 0.040 |
Why?
|
| Immunomagnetic Separation | 1 | 1999 | 8 | 0.040 |
Why?
|
| Azoxymethane | 1 | 1999 | 82 | 0.040 |
Why?
|
| Electrochemistry | 1 | 1999 | 61 | 0.040 |
Why?
|
| Rectum | 1 | 2000 | 148 | 0.040 |
Why?
|
| Cell Nucleus | 2 | 1999 | 594 | 0.040 |
Why?
|
| Carcinogens | 1 | 1999 | 110 | 0.040 |
Why?
|
| Luciferases | 2 | 2011 | 128 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2000 | 353 | 0.040 |
Why?
|
| Uracil | 1 | 1999 | 56 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2014 | 575 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1246 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 84 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1998 | 20 | 0.040 |
Why?
|
| Peroxidases | 1 | 1998 | 34 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 431 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 1155 | 0.040 |
Why?
|
| bcl-X Protein | 1 | 1998 | 54 | 0.040 |
Why?
|
| Esters | 1 | 1998 | 29 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 994 | 0.040 |
Why?
|
| Protein Binding | 2 | 2007 | 1482 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2018 | 68 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 432 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2000 | 464 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1998 | 142 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 189 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2017 | 76 | 0.040 |
Why?
|
| Thymidylate Synthase | 1 | 1997 | 13 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 2 | 1994 | 101 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 3 | 2009 | 37 | 0.040 |
Why?
|
| Leukemia P388 | 2 | 1989 | 3 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1998 | 196 | 0.040 |
Why?
|
| Speech Reception Threshold Test | 1 | 2016 | 4 | 0.040 |
Why?
|
| Hearing Loss, Noise-Induced | 1 | 2016 | 4 | 0.040 |
Why?
|
| Auditory Threshold | 1 | 2016 | 17 | 0.040 |
Why?
|
| Swine | 1 | 1998 | 578 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 630 | 0.030 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2016 | 25 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1999 | 437 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 1989 | 105 | 0.030 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 1996 | 20 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1988 | 312 | 0.030 |
Why?
|
| Hearing Loss, Conductive | 1 | 2016 | 17 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2017 | 236 | 0.030 |
Why?
|
| Phenobarbital | 1 | 1995 | 33 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 386 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2017 | 226 | 0.030 |
Why?
|
| Breast | 1 | 2017 | 290 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 1995 | 88 | 0.030 |
Why?
|
| Azepines | 1 | 2015 | 23 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Prednisone | 1 | 2016 | 258 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hydroxylation | 1 | 2015 | 17 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2015 | 20 | 0.030 |
Why?
|
| RNA, Transfer | 2 | 1988 | 159 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 1999 | 546 | 0.030 |
Why?
|
| Pharmacogenomic Testing | 1 | 2016 | 98 | 0.030 |
Why?
|
| Deuterium | 1 | 2015 | 33 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2015 | 42 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2015 | 58 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 2015 | 52 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 253 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2016 | 286 | 0.030 |
Why?
|
| Catalysis | 1 | 2015 | 204 | 0.030 |
Why?
|
| Triazoles | 1 | 2015 | 100 | 0.030 |
Why?
|
| DNA Polymerase I | 1 | 1994 | 9 | 0.030 |
Why?
|
| DNA Polymerase II | 1 | 1994 | 8 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 2019 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 1704 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2014 | 120 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2014 | 52 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 85 | 0.030 |
Why?
|
| Body Composition | 1 | 2014 | 70 | 0.030 |
Why?
|
| Genetics, Medical | 1 | 2014 | 52 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2014 | 100 | 0.030 |
Why?
|
| Systems Biology | 1 | 2014 | 44 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 385 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 846 | 0.030 |
Why?
|
| Species Specificity | 2 | 1993 | 684 | 0.030 |
Why?
|
| Idoxuridine | 1 | 1993 | 16 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1978 | 0.030 |
Why?
|
| Simvastatin | 1 | 2014 | 105 | 0.030 |
Why?
|
| Cladribine | 1 | 2013 | 35 | 0.030 |
Why?
|
| Dimethylhydrazines | 1 | 1993 | 2 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2013 | 67 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 753 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 122 | 0.030 |
Why?
|
| Solubility | 1 | 1994 | 178 | 0.030 |
Why?
|
| Azacitidine | 1 | 2014 | 139 | 0.030 |
Why?
|
| Suppression, Genetic | 1 | 2013 | 30 | 0.030 |
Why?
|
| RNA Isoforms | 1 | 2012 | 5 | 0.030 |
Why?
|
| Necrosis | 1 | 2013 | 210 | 0.030 |
Why?
|
| Interferon-alpha | 3 | 2000 | 235 | 0.030 |
Why?
|
| Cysteine | 1 | 1993 | 136 | 0.030 |
Why?
|
| Kidney Tubules | 1 | 2013 | 92 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2013 | 48 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 223 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2012 | 43 | 0.030 |
Why?
|
| Thionucleosides | 1 | 2012 | 8 | 0.030 |
Why?
|
| Pilot Projects | 1 | 1995 | 865 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 1093 | 0.030 |
Why?
|
| Caspase 9 | 1 | 2012 | 49 | 0.030 |
Why?
|
| Deoxyadenosines | 1 | 2012 | 23 | 0.030 |
Why?
|
| Chromatin | 1 | 2015 | 396 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2014 | 367 | 0.030 |
Why?
|
| Purines | 1 | 1992 | 93 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2015 | 407 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 96 | 0.030 |
Why?
|
| Histones | 1 | 2014 | 326 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2013 | 109 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 1993 | 170 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2010 | 705 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1712 | 0.030 |
Why?
|
| Cell-Free System | 1 | 1991 | 51 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 1992 | 92 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2011 | 33 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 1995 | 798 | 0.020 |
Why?
|
| Melanoma | 1 | 1996 | 462 | 0.020 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2011 | 30 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2013 | 194 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 73 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 259 | 0.020 |
Why?
|
| Immunohistochemistry | 3 | 2006 | 1788 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 863 | 0.020 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 38 | 0.020 |
Why?
|
| Paresthesia | 1 | 2010 | 16 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1991 | 379 | 0.020 |
Why?
|
| Infertility, Male | 1 | 2010 | 24 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1841 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 1991 | 698 | 0.020 |
Why?
|
| Employment | 1 | 2010 | 53 | 0.020 |
Why?
|
| Tissue Extracts | 1 | 1990 | 24 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 836 | 0.020 |
Why?
|
| Thrombocytopenia | 2 | 2006 | 185 | 0.020 |
Why?
|
| Mitoguazone | 1 | 1989 | 2 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2012 | 884 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2010 | 309 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 102 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 1990 | 193 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2005 | 1095 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 2000 | 1709 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1990 | 307 | 0.020 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 1 | 2009 | 8 | 0.020 |
Why?
|
| Glucuronides | 1 | 2009 | 34 | 0.020 |
Why?
|
| Fatigue | 1 | 2010 | 178 | 0.020 |
Why?
|
| Organic Anion Transporters | 1 | 2009 | 26 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1990 | 314 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2009 | 55 | 0.020 |
Why?
|
| Bilirubin | 1 | 2009 | 130 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 1995 | 768 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2009 | 80 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 594 | 0.020 |
Why?
|
| Pulmonary Fibrosis | 1 | 2010 | 129 | 0.020 |
Why?
|
| Disease Progression | 2 | 2005 | 1489 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2009 | 131 | 0.020 |
Why?
|
| Calcium | 1 | 1993 | 1170 | 0.020 |
Why?
|
| Thiosemicarbazones | 1 | 2008 | 6 | 0.020 |
Why?
|
| Methemoglobinemia | 1 | 2008 | 10 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 37 | 0.020 |
Why?
|
| DNA Glycosylases | 1 | 1988 | 25 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2012 | 1294 | 0.020 |
Why?
|
| Ovary | 1 | 1989 | 261 | 0.020 |
Why?
|
| Glucuronosyltransferase | 1 | 2009 | 185 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 258 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 429 | 0.020 |
Why?
|
| Microsatellite Instability | 1 | 2007 | 49 | 0.020 |
Why?
|
| Informatics | 1 | 2007 | 5 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2007 | 137 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 78 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2009 | 330 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2008 | 119 | 0.020 |
Why?
|
| Forecasting | 1 | 2008 | 305 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 665 | 0.020 |
Why?
|
| RNA, Ribosomal | 1 | 1987 | 63 | 0.020 |
Why?
|
| Hydroxyurea | 2 | 2000 | 239 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2017 | 8859 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2007 | 54 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2007 | 266 | 0.020 |
Why?
|
| Leucovorin | 2 | 1997 | 222 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 408 | 0.020 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2006 | 16 | 0.020 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2006 | 23 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2007 | 425 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2005 | 25 | 0.020 |
Why?
|
| Pyridines | 1 | 2008 | 316 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2007 | 141 | 0.020 |
Why?
|
| Leiomyosarcoma | 1 | 2006 | 43 | 0.020 |
Why?
|
| Cognition | 1 | 2010 | 577 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2008 | 404 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 689 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2005 | 65 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2005 | 205 | 0.020 |
Why?
|
| Anemia | 1 | 2006 | 126 | 0.020 |
Why?
|
| Toxicity Tests | 1 | 2004 | 13 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2007 | 268 | 0.020 |
Why?
|
| Recurrence | 1 | 2008 | 1168 | 0.020 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2003 | 4 | 0.010 |
Why?
|
| Leukemia L1210 | 1 | 1983 | 12 | 0.010 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2003 | 6 | 0.010 |
Why?
|
| RNA | 1 | 1988 | 575 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 321 | 0.010 |
Why?
|
| Remission Induction | 2 | 1997 | 734 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 408 | 0.010 |
Why?
|
| Life Tables | 1 | 2002 | 48 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1860 | 0.010 |
Why?
|
| Selenoproteins | 1 | 2001 | 20 | 0.010 |
Why?
|
| Gliosarcoma | 1 | 2000 | 7 | 0.010 |
Why?
|
| Drug Implants | 1 | 2000 | 34 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2000 | 156 | 0.010 |
Why?
|
| Stereotaxic Techniques | 1 | 2000 | 78 | 0.010 |
Why?
|
| Benzophenanthridines | 1 | 2000 | 23 | 0.010 |
Why?
|
| Alkaloids | 1 | 2000 | 46 | 0.010 |
Why?
|
| Tretinoin | 1 | 2000 | 128 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2000 | 471 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2000 | 268 | 0.010 |
Why?
|
| Cerebellar Neoplasms | 1 | 1999 | 36 | 0.010 |
Why?
|
| Rats, Nude | 1 | 1997 | 23 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1997 | 33 | 0.010 |
Why?
|
| Radiography | 1 | 1999 | 806 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1999 | 771 | 0.010 |
Why?
|
| Tetrahydrofolates | 1 | 1996 | 13 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1996 | 102 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1998 | 398 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 69 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1996 | 69 | 0.010 |
Why?
|
| Procarbazine | 1 | 1995 | 40 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1996 | 284 | 0.010 |
Why?
|
| Bile | 1 | 1994 | 57 | 0.010 |
Why?
|
| Topotecan | 1 | 1994 | 45 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 1995 | 331 | 0.010 |
Why?
|
| Antimutagenic Agents | 1 | 1993 | 7 | 0.010 |
Why?
|
| Biogenic Polyamines | 1 | 1993 | 2 | 0.010 |
Why?
|
| Ornithine Decarboxylase | 1 | 1993 | 9 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1991 | 2440 | 0.010 |
Why?
|
| Monocytes | 1 | 1994 | 217 | 0.010 |
Why?
|
| Diploidy | 1 | 1991 | 31 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1995 | 437 | 0.010 |
Why?
|
| Diet | 1 | 1993 | 442 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1991 | 531 | 0.010 |
Why?
|
| Colon | 1 | 1993 | 502 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1996 | 1226 | 0.010 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 1988 | 7 | 0.000 |
Why?
|
| Mammals | 1 | 1988 | 234 | 0.000 |
Why?
|
| Thymus Gland | 1 | 1985 | 197 | 0.000 |
Why?
|
| Skin | 1 | 1985 | 577 | 0.000 |
Why?
|